Searchable abstracts of presentations at key conferences in endocrinology

ea0038oc5.6 | Thyroid and parathyroid | SFEBES2015

Safety review of liothyronine use: a 20 year observational follow up study

Soto-Pedre Enrique , Leese Graham

Some patients use liothyronine as thyroid replacement therapy as an alternative to L-thyroxine. Trials have examined the potential benefits, but there is little data looking at the relative safety of these two agents. All patients receiving thyroid replacement therapy between 1993 and 2014 in Tayside were included in a cohort study (n=34 355; 319 500 patient years of follow up). Overall 33 955 patients received only L-thyroxine, and 327 r...

ea0029p1474 | Pituitary Clinical | ICEECE2012

Long-term outcomes after sterotactic radiosurgery for non-functioning pituitary adenomas

Suleiman Y , Vilchez R , Roman A , Soto A , Venegas E , Soto A , Atutxa A , Martin J , Torres E

Introduction: Sterotactic radiosurgery (SR) has been used to treat recurrent adenomas and also as a primary treatment. The objective is to evaluate long-term tumor control, development of hypopituitarism and other side effects in the follow-up.Patients and method: Retrospective analysis of 21 patients with non-functioning pituitary adenomas (NFA) treated with modified linear accelerator (LINAC) between 1998 and 2009 in three tertiary Spanish hospitals. C...

ea0050p261 | Neuroendocrinology and Pituitary | SFEBES2017

Morbidity and mortality in patients with hyperprolactinaemia: The prolactin epidemiology, audit, and research study (PROLEARS)

Soto-Pedre Enrique , Newey Paul , Bevan John , Leese Graham

Purpose: High serum prolactin concentrations have been associated with adverse health outcomes in some but not all studies. This study aimed to examine the morbidity and all-cause mortality associated with hyperprolactinaemia.Methods: A population-based matched cohort study in Tayside (Scotland, UK) from 1988 to 2014. Record-linkage technology (biochemistry, prescribing, hospital admissions, cancer registration, mat...

ea0050p261 | Neuroendocrinology and Pituitary | SFEBES2017

Morbidity and mortality in patients with hyperprolactinaemia: The prolactin epidemiology, audit, and research study (PROLEARS)

Soto-Pedre Enrique , Newey Paul , Bevan John , Leese Graham

Purpose: High serum prolactin concentrations have been associated with adverse health outcomes in some but not all studies. This study aimed to examine the morbidity and all-cause mortality associated with hyperprolactinaemia.Methods: A population-based matched cohort study in Tayside (Scotland, UK) from 1988 to 2014. Record-linkage technology (biochemistry, prescribing, hospital admissions, cancer registration, mat...

ea0038p29 | Clinical biochemistry | SFEBES2015

The epidemiology of hyperprolactinaemia

Soto-Pedre Enrique , Newey Paul , Bevan John , Leese Graham

The epidemiology of hyperprolactinaemia is not well characterised in the literature. Using unique patient identifier we were able to link data from biochemistry, prescribing, hospital admissions, radiology, general registry office and maternity data. Observational data was collected for Tayside Scotland between 1993 and 2013. Any patient with a serum prolactin measurement >1000 mU/l or at least three prescriptions for a dopamine agonist were included. Patients who were pre...

ea0056p489 | Diabetes therapy | ECE2018

Dulaglutide; effectiveness in a real world population with type 2 diabetes

Linares Lidia Urbon Lopez de , Soto Cristina Crespo

Diabetes is a chronic disease that is often accompanied by multiple comorbidities and health complications such as overweight/obesity. In the late years therapies improving glycemic control while reducing body weight have become a convenient choice to treat diabetes. One of those therapies are GLP 1 receptor agonists. Dulaglutide allows for a once weekly dosing which might improve compliance; moreover its new application device ease the injection. We show the results of HbA1c ...

ea0050p381 | Thyroid | SFEBES2017

Genetic variants modify susceptibility to AF in patients on thyroid hormone replacement therapy

Soto-Pedre Enrique , Siddiqui Moneeza , Doney Alex , Palmer Colin , Pearson Ewan , Leese Graham

Purpose: Hypothyroidism has been associated with atrial fibrillation (AF) in some studies. This study aimed to characterize thyroid related genetic variants that may change susceptibility to AF in patients on thyroid hormone replacement therapy (levothyroxine).Methods: A case-control study was done among patients of European Caucasian ethnicity from the Genetics of Diabetes Audit and Research Tayside (GoDARTS) recruited in Tayside (Scotland...

ea0050p381 | Thyroid | SFEBES2017

Genetic variants modify susceptibility to AF in patients on thyroid hormone replacement therapy

Soto-Pedre Enrique , Siddiqui Moneeza , Doney Alex , Palmer Colin , Pearson Ewan , Leese Graham

Purpose: Hypothyroidism has been associated with atrial fibrillation (AF) in some studies. This study aimed to characterize thyroid related genetic variants that may change susceptibility to AF in patients on thyroid hormone replacement therapy (levothyroxine).Methods: A case-control study was done among patients of European Caucasian ethnicity from the Genetics of Diabetes Audit and Research Tayside (GoDARTS) recruited in Tayside (Scotland...

ea0029p1475 | Pituitary Clinical | ICEECE2012

Long-term outcomes after sterotactic radiosurgery for functioning pituitary adenomas

Suleiman Y , Vilchez R , Roman A , Soto A , Venegas E , Leal A , Atutxa A , Martin J , Torres E

Introduction: Sterotactic radiosurgery (SR) has been used to treat recurrent adenomas after failure of medical and surgical procedures and also as a primary treatment. The aim of this paper is to evaluate long-term control of functioning pituitary adenomas (FPA).Patients and method: Thirty-eight patients with FPA treated with modified linear accelerator (LINAC) between 1998 and 2009 in three tertiary Spanish hospitals. Hormonal control was defined as hor...

ea0022p660 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Trends in acromegaly treatment in Spain

Sesmilo Gemma , Gaztambide Sonia , Pico Antonio , Soto Alfonso , Torres Elena , Fajardo Carmen , Blanco Concepcion , Webb Susan

The Spanish acromegaly registry (REA) is an online epidemiological database created in 1997 to collect clinical and biochemical data of patients with acromegaly followed in Spain.Aim: To study trends in acromegaly treatment over time in Spain.Methods: REA is an online database in which registered endocrinologists collect data from all acromegalic patients seen at their practices in Spain. In the last year the neuroendocrine group o...